The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Double-Hit Gene Expression Signature Defines a Distinct Subgroup of Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma
Open accessAbstract
Purpose: High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements (HGBL-DH/TH) has a poor outcome after standard chemoimmunotherapy. We sought to understand the biologic underpinnings of HGBL-DH/TH with BCL2 rearrangements (HGBL-DH/TH- BCL2) and diffuse large B-cell lymphoma (DLBCL) morphology through examination of gene expression. Patients and Methods: We analyzed RNA sequencing data from 157 de novo germinal center B-cell-like (GCB)-DLBCLs, including 25 with HGBL-DH/TH- BCL2, to define a gene expression signature that distinguishes HGBL-DH/TH- BCL2 from other GCB-DLBCLs. To assess the genetic, molecular, and phenotypic features associated with this signature, we analyzed targeted resequencing, whole-exome sequencing, RNA sequencing, and immunohistochemistry data. Results: We developed a 104-gene double-hit signature (DHITsig) that assigned 27% of GCB-DLBCLs to the DHITsig-positive group, with only one half harboring MYC and BCL2 rearrangements (HGBL-DH/TH- BCL2). DHITsig-positive patients had inferior outcomes after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone immunochemotherapy compared with DHITsig-negative patients (5-year time to progression rate, 57% and 81%, respectively; P < .001), irrespective of HGBL-DH/TH- BCL2 status. The prognostic value of DHITsig was confirmed in an independent validation cohort. DHITsig-positive tumors are biologically characterized by a putative non–light zone germinal center cell of origin and a distinct mutational landscape that comprises genes associated with chromatin modification. A new NanoString assay (DLBCL90) recapitulated the prognostic significance and RNA sequencing assignments. Validating the association with HGBL-DH/TH- BCL2, 11 of 25 DHITsig-positive–transformed follicular lymphomas were classified as HGBL-DH/TH- BCL2 compared with zero of 50 in the DHITsig-negative group. Furthermore, the DHITsig was shared with the majority of B-cell lymphomas with high-grade morphology tested. Conclusion: We have defined a clinically and biologically distinct subgroup of tumors within GCB-DLBCL characterized by a gene expression signature of HGBL-DH/TH- BCL2. This knowledge has been translated into an assay applicable to routinely available biopsy samples, which enables exploration of its utility to guide patient management.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
Alizadeh, A. A., Eisen, M. B., Davis, R. E., Ma, C., Lossos, I. S., Rosenwald, A., Boldrick, J. C., Sabet, H., Tran, T., Yu, X., et al. (2000) · Nature · doi:10.1038/35000501 · Cited by 9,925
The 2016 revision of the World Health Organization classification of lymphoid neoplasms
Swerdlow, S. H., Campo, E., Pileri, S. A., Harris, N. L., Stein, H., Siebert, R., Advani, R., Ghielmini, M., Salles, G. A., Zelenetz, A. D., et al. (2016) · Blood · doi:10.1182/blood-2016-01-643569 · Cited by 7,831
Shipp, M. A., Ross, K. N., Tamayo, P., Weng, A. P., Kutok, J. L., Aguiar, R. C. T., Gaasenbeek, M., Angelo, M., Reich, M., Pinkus, G. S., et al. (2002) · Nature Medicine · doi:10.1038/nm0102-68 · Cited by 2,428
Genetics and pathogenesis of diffuse large B-cell lymphoma
Schmitz, R., Wright, G. W., Huang, D. W., Johnson, C. A., Phelan, J. D., Wang, J. Q., Roulland, S., Kasbekar, M., Young, R. M., Shaffer, A. L., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801445 · Cited by 2,241
Self-citationChapuy, B., Stewart, C., Dunford, A. J., Kim, J., Kamburov, A., Redd, R. A., Lawrence, M. S., Roemer, M. G. M., Li, A. J., Ziepert, M., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0016-8 · Cited by 1,941
Stromal Gene Signatures in Large-B-Cell Lymphomas
Lenz, G., Wright, G., Dave, S. S., Xiao, W., Powell, J., Zhao, H., Xu, W., Tan, B., Goldschmidt, N., Iqbal, J., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802885 · Cited by 1,808
Self-citationFrequent mutation of histone-modifying genes in non-Hodgkin lymphoma
Morin, R. D., Mendez-Lago, M., Mungall, A. J., Goya, R., Mungall, K. L., Corbett, R. D., Johnson, N. A., Severson, T. M., Chiu, R., Field, M., et al. (2011) · Nature · doi:10.1038/nature10351 · Cited by 1,614
Self-citationGenetic and functional drivers of diffuse large B cell lymphoma
Reddy, A., Zhang, J., Davis, N. S., Moffitt, A. B., Love, C. L., Waldrop, A., Leppa, S., Pasanen, A., Meriranta, L., Karjalainen-Lindsberg, M.-L., et al. (2017) · Cell · doi:10.1016/j.cell.2017.09.027 · Cited by 1,104
Johnson, N. A., Slack, G. W., Savage, K. J., Connors, J. M., Ben-Neriah, S., Rogic, S., Scott, D. W., Tan, K. L., Steidl, C., Sehn, L. H., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.41.0985 · Cited by 975
Self-citationLohr, J. G., Stojanov, P., Lawrence, M. S., Auclair, D., Chapuy, B., Sougnez, C., Cruz-Gordillo, P., Knoechel, B., Asmann, Y. W., Slager, S. L., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1121343109 · Cited by 974
Cited by
Alaggio, R., Amador, C., Anagnostopoulos, I., Attygalle, A. D., Araujo, I. B. D. O., Berti, E., Bhagat, G., Borges, A. M., Boyer, D., Calaminici, M., et al. (2022) · Leukemia · doi:10.1038/s41375-022-01620-2 · Cited by 4,004
Campo, E., Jaffe, E. S., Cook, J. R., Quintanilla-Martinez, L., Swerdlow, S. H., Anderson, K. C., Brousset, P., Cerroni, L., de Leval, L., Dirnhofer, S., et al. (2022) · Blood · doi:10.1182/blood.2022015851 · Cited by 1,608
Self-citationSehn, L. H., & Salles, G. (2021) · New England Journal of Medicine · doi:10.1056/nejmra2027612 · Cited by 1,175
Self-citationWright, G. W., Huang, D. W., Phelan, J. D., Coulibaly, Z. A., Roulland, S., Young, R. M., Wang, J. Q., Schmitz, R., Morin, R. D., Tang, J., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.03.015 · Cited by 1,169
Self-citationPolatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma
Tilly, H., Morschhauser, F., Sehn, L. H., Friedberg, J. W., Trněný, M., Sharman, J. P., Herbaux, C., Burke, J. M., Matasar, M., Rai, S., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2115304 · Cited by 926
Self-citationDiffuse large B‐cell lymphoma: 2019 update on diagnosis, risk stratification, and treatment
Liu, Y., & Barta, S. K. (2019) · American Journal of Hematology · doi:10.1002/ajh.25460 · Cited by 488
Susanibar‐Adaniya, S., & Barta, S. K. (2021) · American Journal of Hematology · doi:10.1002/ajh.26151 · Cited by 388
Patel, S. P., Othus, M., Chae, Y. K., Giles, F. J., Hansel, D. E., Singh, P. P., Fontaine, A., Shah, M. H., Kasi, A., Baghdadi, T. A., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3356 · Cited by 345
The landscape of tumor cell states and ecosystems in diffuse large B cell lymphoma
Steen, C. B., Luca, B. A., Esfahani, M. S., Azizi, A., Sworder, B. J., Nabet, B. Y., Kurtz, D. M., Liu, C. L., Khameneh, F., Advani, R. H., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.08.011 · Cited by 332
Effect of ibrutinib with R-CHOP chemotherapy in genetic subtypes of DLBCL
Wilson, W. H., Wright, G. W., Huang, D. W., Hodkinson, B., Balasubramanian, S., Fan, Y., Vermeulen, J., Shreeve, M., & Staudt, L. M. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.10.006 · Cited by 315
Grande, B. M., Gerhard, D. S., Jiang, A., Griner, N. B., Abramson, J. S., Alexander, T. B., Allen, H., Ayers, L. W., Bethony, J. M., Bhatia, K., et al. (2019) · Blood · doi:10.1182/blood-2018-09-871418 · Cited by 270
Self-citationClinical and Biological Subtypes of B-cell Lymphoma Revealed by Microenvironmental Signatures
Kotlov, N., Bagaev, A., Revuelta, M. V., Phillip, J. M., Cacciapuoti, M. T., Antysheva, Z., Svekolkin, V., Tikhonova, E., Miheecheva, N., Kuzkina, N., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0839 · Cited by 267
Targeting immune checkpoints in hematological malignancies
Salik, B., Smyth, M. J., & Nakamura, K. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00947-6 · Cited by 113
Qiu, Z., Khalife, J., Ethiraj, P., Jaafar, C., Lin, A.-P., Holder, K. N., Ritter, J. P., Chiou, L., Huelgas-Morales, G., Aslam, S., et al. (2024) · Science Advances · doi:10.1126/sciadv.adk2091 · Cited by 25
Metadata
- Authors
- Ennishi, D., Jiang, A., Boyle, M., Collinge, B., Grande, B. M., Ben-Neriah, S., Rushton, C., Tang, J., Thomas, N., Slack, G. W., Farinha, P., Takata, K., Miyata-Takata, T., Craig, J., Mottok, A., Meissner, B., Saberi, S., Bashashati, A., Villa, D., Savage, K. J., Sehn, L. H., Kridel, R., Mungall, A. J., Marra, M. A., Shah, S. P., Steidl, C., Connors, J. M., Gascoyne, R. D., Morin, R. D., & Scott, D. W.
- Venue
- Journal of Clinical Oncology
- Published
- 2019-01-20
- Volume
- 37
- Issue
- 3
- Pages
- 190-201
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2903278833
- Cited by
- 414
- References
- 29
- FWCI
- 22.98
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.